What does ERAS change after breast augmentation?

Enhanced recovery after surgery (ERAS) is a coordinated plan for care before, during and after an operation. Its components are intended to address different parts of the perioperative experience: clear preparation can help people understand the plan and set realistic expectations; pain-control and anaesthetic choices aim to manage surgical discomfort and nausea; and early, supported movement, discharge criteria and follow-up contact help the team assess readiness and respond to problems. The pathway is a bundle, so an outcome after the bundle cannot show which component produced it. For implant-based breast augmentation, the most direct comparison is a prospective study of 122 patients. A separate cohort described one detailed pathway but followed several kinds of aesthetic breast surgery.

What the randomised augmentation study measured

Xia and colleagues prospectively recruited people undergoing implant-based breast augmentation from December 2020 to January 2023. The abstract reports 122 participants: 70 were randomly assigned to a standardised ERAS pathway and 52 to non-ERAS care. It names Peking Union Medical College Hospital in Beijing in the author affiliations, although the abstract does not explicitly state the recruitment site. The primary outcome was activity of daily living; pain was secondary. Other listed outcomes included time to free upper-limb elevation, vomiting, analgesic use and complications. [1]

The ERAS group reached free elevation of the upper limbs after 2.3 days, compared with 5.5 days in the comparison group (P<0.001). Pain scores were significantly lower and the activity-of-daily-living index significantly higher on postoperative days 1, 2 and 3. However, the abstract does not provide the actual scores, the scales used, effect sizes or confidence intervals for those outcomes. It also reports opioid consumption of 7.1 mg versus 46.2 mg (P=0.018), without specifying in the abstract which opioid-equivalence measure or collection period those milligrams represent.

These outcomes describe different things. Raising the arms freely is not equivalent to being pain-free, managing every usual task, returning to work or exercise, or completing tissue healing. The reported opioid difference cannot be converted into morphine equivalents from the abstract and does not mean that the ERAS group avoided opioids.

What can and cannot be inferred from that comparison

The authors reported no difference in complications or hospital costs between the groups. With 122 participants, this does not establish that the pathway prevents complications or that risks are identical: a study of this size may not detect uncommon events, and the abstract supplies no event counts or confidence intervals. The abstract also does not give enough detail to assess allocation concealment, blinding, adherence to the pathway, the exact comparator care, or how missing outcomes were handled.

There is a classification caveat. PubMed lists the paper as a randomised controlled trial, while the journal labels it Level of Evidence IV. Those labels are both reported by the source; without the full methods, the difference cannot be resolved here. The result is promising direct evidence, but it should be read as an early study rather than a settled estimate of what every clinic or patient can expect.

What a separate patient-reported cohort adds

Stahl and colleagues followed consecutive patients at one centre from April 2021 to August 2022. Of the patients considered, two were excluded because of operative revision and one because of an incomplete questionnaire; 48 were included. This exclusion of people with a revision or incomplete data may limit how representative the results are. Nearly half of the procedures were breast augmentations, 35% were reductions and about 17% were gynecomastia corrections; mastopexy was performed in 23% of patients, and 69% of procedures included an additional operation such as liposuction. These categories can overlap. This was a mixed-procedure cohort, not a controlled augmentation-only trial. [2]

Across this mixed cohort, patients reported being able to do most daily activities within five days. The paper reports that 71% performed most activities sooner than they had expected (P<0.001); its abstract separately says 88% were able to accomplish daily activities sooner than expected. Those percentages refer to different reported summaries in the paper and should not be merged into one estimate. The full report describes activities returning at different times: walking around the home and climbing stairs came first; dressing and an outdoor walk were reported on the following day, cooking and showering on the second day, housework and shopping around the fourth day, and driving around the fifth day. These are group reports from a mixed-procedure cohort, not instructions or a timetable for an individual.

The cohort pathway helps explain how ERAS components may fit together, although it cannot isolate their effects. Before surgery, patients had at least two counselling appointments and written instructions about preparation and recovery. The pathway used sedation rather than general anaesthesia, with intercostal nerve blocks and local anaesthesia; these approaches were intended to manage pain while supporting an outpatient pathway. Communication, warming measures and the anaesthetic plan addressed comfort and temperature during the operation. Afterwards, patients were encouraged to walk early, and discharge depended on tolerating food, passing urine, walking without assistance, and having no intolerable pain or nausea. Written instructions, scheduled follow-up, telephone access to the surgeon and a same-day call provided routes for questions after discharge. These are features of the study protocol, not proof that each element caused faster recovery or a standard that every patient should receive.

For the activity questionnaire, patients estimated before surgery when they expected to manage tasks, then reported when they felt able to do them during the first week; the scale ran from 0 (day of surgery) to 8 (after one week). The paper reports medians and interquartile ranges (IQR), not a universal recovery date. For normal daily activities, the median was 2 days after augmentation (IQR 1–2), 2 days after reduction (IQR 1–3), and 2 days after gynecomastia surgery (IQR 1–2). The augmentation category combined implant-only, fat-transfer-only and hybrid augmentation; these timings therefore do not describe implant-only patients. In that combined augmentation category, the median questionnaire score for driving up to 50 km was 5 (IQR 2–8). Because score 8 means after one week, the upper quartile extends beyond the first week rather than identifying an exact eighth-day return. Housework had a median score of 5 (IQR 4–5), and shopping 4 (IQR 3–5). These are self-reported group summaries under this pathway and setting; driving and household activity do not establish readiness for work, exercise or travel. The paper used BREAST-Q or BODY-Q modules for satisfaction, whose Rasch-transformed scores range from 0 to 100, with higher scores indicating greater satisfaction. These satisfaction questionnaires were completed at least four weeks after surgery; the recovery questionnaire was completed ten days after surgery. Satisfaction scores are not a pain or recovery-time scale.

The study found no statistically significant difference in postoperative satisfaction between the 12% who recovered more slowly than anticipated and the 88% who recovered as quickly as or faster than anticipated (P=0.180). The paper reports that moderate-to-very-strong concern about conscious sedation fell from 17% before surgery to 4% afterwards (P<0.001). Because there was no comparison group, these observations cannot show that ERAS caused the activity pattern, satisfaction or change in anxiety. Although the authors report procedure-specific daily-activity medians, their cohort design does not establish how the same patients would have recovered under another pathway.

Why reconstruction guidance is only indirect context

An ERAS Society-endorsed consensus review considered perioperative care for breast reconstruction. Its panel reviewed meta-analyses, randomised trials and large prospective cohorts where available, using smaller or retrospective studies when stronger evidence was lacking. It developed recommendations across 18 pathway items, including opioid-sparing pain strategies, shorter fasting with early feeding, reducing nausea and pain, avoiding hypothermia and early mobilisation. The authors noted that high-quality reconstruction-specific trials informed only some recommendations; for many items, lower-level reconstruction evidence or evidence extrapolated from other populations was used. [3]

Reconstruction after cancer surgery can involve mastectomy, tissue flaps, cancer treatment and monitoring needs that do not apply to routine cosmetic augmentation. The consensus review can help explain why a coordinated pathway has several components, but it is not a trial of cosmetic augmentation and cannot supply its recovery estimates or prove the same effects.

Questions to discuss when planning recovery

Ask for an itemised estimate that separates the operation, anaesthesia, follow-up and any additional care, since price pages may describe a different scope; see the breast augmentation cost in Turkey as a starting point for questions, not as a clinical estimate. If a package is proposed, ask the clinical team to confirm in writing which appointments, aftercare and follow-up are actually included; the breast augmentation package details do not establish that ERAS measures or a particular recovery service are included.

• Which parts of the proposed pathway are used in my case, and what is the reason for each?
• What pain relief is planned, including what to do if pain is not controlled or a medicine causes side effects?
• Which arm and upper-body movements are encouraged or restricted, and how will advice change over time?
• What specific signs should prompt a call, urgent assessment or emergency care, and who is available outside normal hours?
• What criteria will guide driving, work, lifting, exercise and travel? How do my operation, health, medicines and journey affect that advice?
• What follow-up is arranged after discharge, and how can I contact the clinical team if recovery differs from expectations?

The studies do not establish a safe travel date, a return-to-work date or a universal exercise schedule. Those decisions require advice from the treating clinical team, taking account of the actual procedure and individual recovery. Just Clinic Istanbul is an independent marketing and lead generation platform, not a healthcare provider or medical tourism intermediary. Enquiries may be shared with authorised healthcare partners with your consent.

Related information

For related research, read about multimodal pain relief after breast augmentation. See also the separate discussion of safety questions about breast augmentation in Turkey.

References

1. Xia Z, Chen Y, Xie J, Zhang W, Tan L, Shi Y, Liu J, Wang X, Tan G, Zeng A. Faster Return to Daily Activities and Better Pain Control: A Prospective Study of Enhanced Recovery After Surgery Protocol in Breast Augmentation. Aesthetic Plastic Surgery. First published online 24 July 2023; 47(6):2261–2267, December 2023. doi: 10.1007/s00266-023-03504-x. PMID: 37488312.
2. Stahl S, Santos Stahl A, Feng Y-S, Estler A, Buiculescu F, Seabra Robalo Gomes Jorge AC. Enhanced Recovery After Surgery (ERAS) Pathways for Aesthetic Breast Surgery: A Prospective Cohort Study on Patient-Reported Outcomes. Aesthetic Plastic Surgery. First published online 1 June 2023; 48(2):84–94, January 2024. doi: 10.1007/s00266-023-03392-1. PMID: 37261492. Full text: PMC10234236.
3. Temple-Oberle C, Shea-Budgell MA, Tan M, Semple JL, Schrag C, Barreto M, Blondeel P, Hamming J, Dayan J, Ljungqvist O; ERAS Society. Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations. Plastic and Reconstructive Surgery. May 2017; 139(5):1056e–1071e. doi: 10.1097/PRS.0000000000003242. PMID: 28445352. Full text: PMC9074892.